| Literature DB >> 26880854 |
Jolanta Dadoniene1, Alma Cypiene2, Ligita Ryliskyte3, Rita Rugiene1, Kristina Ryliškiene4, Aleksandras Laucevičius2.
Abstract
Skin autofluorescence (AF), a relatively simple and time saving procedure, measures the accumulation of advanced glycation end (AGE) products. The importance in autoimmune rheumatic diseases, particularly, systemic sclerosis (SSc), has not been evaluated yet. The aim of our study was to examine the skin AF in the context of SSc patients and to analyse the relations between skin AF and other surrogate measures of atherosclerosis. Forty-seven patients with SSc and 47 healthy volunteers were included in this study as controls. Patients and controls underwent common carotid artery wall assessment, arterial stiffness and wave reflection measurements, laser Doppler measurements of capillary flow, assessment of endothelial function by brachial ultrasound, peripheral arterial tonometry, and AGE measurement by skin AF. Wall properties of the common carotid arteries and wave reflection measurements were not affected in these study patients compared to controls while measures reflecting small capillary flow were altered. The accumulation of AGE products measured by skin AF was more prominent in SSc patients than in healthy controls. AGE products' score was significantly associated with carotid radial pulse wave velocity, intima media/carotid artery diameter ratio, capillary flow percentage change during occlusion, and the disease itself in a multivariate linear analysis model.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26880854 PMCID: PMC4736188 DOI: 10.1155/2015/837470
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Main characteristics of 47 systemic sclerosis patients matched by age and gender to 47 healthy controls.
| Systemic sclerosis patients | Healthy controls |
| |
|---|---|---|---|
| Mean age, years | 52.64 (SD 11.20) | 52.57 (SD 7.69) | 0.974 |
| Gender, female, nr (%) | 41 (87.2%) | 41 (87.2%) | 1.00 |
| Body mass index, kg/m2 | 24.27 (SD 4.63) | 26.09 (SD 4.50) | 0.06 |
| Total cholesterol, mmol/L | 5.80 (1.46) | 6.22 (1.13) | 0.132 |
| Low density lipoprotein cholesterol, mmol/L | 3.6651 (SD 1.33) | 4.1088 (SD 0.99) | 0.083 |
| High density lipoprotein cholesterol, mmol/L | 1.35 (SD 0.38) | 1.57 (SD 0.34) | 0.006 |
| Triglycerides, mmol/L | 1.53 (SD 0.68) | 1.15 (SD 0.53) | 0.005 |
Clinical characteristics of 47 systemic sclerosis patients.
| Disease duration, years | 12.70 (SD 9.52), min–max (1–40) |
| Rodnan skin thickness score | 13.30 (SD 7.21), min–max (2–30) |
| Subtype of systemic sclerosis | |
| Limited nr, % | 35, 74.5% |
| Diffuse nr, % | 12, 25.5% |
| Capillaroscopy evaluation | |
| Active nr, % | 17, 36.2% |
| Late nr, % | 20, 42.6% |
| Early nr, % | 10, 21.3% |
| Treatment during the last half a year | |
| ACE inhibitors nr, % | 8, 17.0% |
| Calcium channels blockers nr, % | 37, 78.7% |
| Methotrexate nr, % | 8, 17.0% |
| Azathioprine nr, % | 8, 17.0% |
| Antimalarials nr, % | 5, 10.64% |
| Steroids nr, % | 23, 48.94% |
Arterial wall or capillary flow assessment and comparison between systemic sclerosis and healthy controls.
| Measurement | Systemic sclerosis patients ( | Healthy controls ( |
|
|---|---|---|---|
|
| |||
| (IMT/CCA) | 9.34 (3.81–12.99) | 9.56 (6.90–49.53) | 0.141 |
| Stiffness of carotid arteries (mean of right and left) | 3.80 (SD 1.67) | 3.75 (SD 1.47) | 0.882 |
|
| |||
| Mean blood pressure, mmHg | 93.98 (SD 12.81) | 96.60 (SD 7.93) | 0.237 |
| Pulse wave velocity (carotid femoral), m/sec | 7.53 (SD 1.70) | 7.51 (SD 1.30) | 0.962 |
| Pulse wave velocity (carotid radial), m/sec | 8.96 (SD 1.60) | 8.61 (SD 1.19) | 0.227 |
| Augmentation index (adj. for 75 heart rate) | 26.02 (SD 12.08) | 24.89 (SD 9.66) | 0.618 |
|
| |||
| Postocclusive hyperaemia | |||
| Rest flow median before occlusion, PU (min–max) | 29.51 (8.00–225.74) | 32.66 (8.5–171.99) | 0.308 |
| Time to peak hyperaemia, sec | 00:34.410 (00:13.860–04:55.930) | 00:33.755 (00:05.860–05:37.710) | 0.121 |
| Percentage change median between rest and peak flow (min–max) | 346.71 (7.10–2.344.74) | 383.46 (0.83–909.67) | 0.546 |
| Thermal response | |||
| Rest flow median before heating, PU, (min–max) | 27.71 (0.81–114.02) | 46.53 (4.66–388.74) | 0.008 |
| Maximal flow in response to heating, PU | 217.01 (SD 150.05) | 354.95 (SD 144.41) | <0.001 |
| Time to maximal flow | 00:23:47 (00:17:59–00:28:35) | 00:22:31 (00:16:31–00:28:01) | 0.097 |
| Cold stimulation | |||
| Rest flow median before cooling, PU, (min–max) | 84.94 (4.49–388.18) | 165.10 (10.67–635.23) | 0.178 |
| Minimal flow in response to cooling, PU, (min–max) | 11.00 (−0.10–196.10) | 72.40 (2.10–435.90) | 0.002 |
| Time to minimal flow | 00:07:09 (00:05:52–00:09:44) | 00:06:29 (00:05:04–00:09:58) | 0.052 |
|
| |||
| Flow mediated dilatation, percentage change | 3.24 (SD 2.19) | 3.83 (SD 2.48) | 0.227 |
|
| |||
| Reactive hyperaemia index | 1.50 (SD 0.53) | 2.00 (SD 0.52) | <0.001 |
|
| |||
| Autofluorescence index | 2.23 (SD 0.54) | 1.90 (SD 0.47) | 0.007 |
Predictors of an advanced glycation end product score.
| Advanced glycation end product score | Independent variables | Standardized coefficient beta | Statistical significance for standardized coefficient beta |
|
| |||
|
Adjusted determination coefficient for stepwise multiple regression model | Pulse wave velocity (carotid radial), m/sec | 0.297 | 0.010 |
| (IMT/CCA) | 0.388 | 0.002 | |
| Percentage change median between rest and peak flow | 0.245 | 0.032 | |
| Systemic sclerosis (1)/healthy (0) | 0.323 | 0.007 | |